Investigator

Letizia Vallino

Post Doctoral Researcher · Università degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Scienze della Salute, Scienze della salute

Research Interests

LVLetizia Vallino
Papers(2)
Glycolysis Inhibition…Ovarian Cancer Cell-C…
Collaborators(6)
Alessandra FerraresiCiro IsidoroDanny N. DhanasekaranBeatrice GaravagliaChinmay MaheshwariJi Hee Ha
Institutions(3)
Universit Degli Studi…University Of OklahomaUnknown Institution

Papers

Glycolysis Inhibition of Autophagy Drives Malignancy in Ovarian Cancer: Exacerbation by IL-6 and Attenuation by Resveratrol

Cancer cells drive the glycolytic process towards the fermentation of pyruvate into lactate even in the presence of oxygen and functioning mitochondria, a phenomenon known as the “Warburg effect”. Although not energetically efficient, glycolysis allows the cancer cell to synthesize the metabolites needed for cell duplication. Autophagy, a macromolecular degradation process, limits cell mass accumulation and opposes to cell proliferation as well as to cell migration. Cancer cells corrupt cancer-associated fibroblasts to release pro-inflammatory cytokines, which in turn promote glycolysis and support the metastatic dissemination of cancer cells. In mimicking in vitro this condition, we show that IL-6 promotes ovarian cancer cell migration only in the presence of glycolysis. The nutraceutical resveratrol (RV) counteracts glucose uptake and metabolism, reduces the production of reactive oxygen species consequent to excessive glycolysis, rescues the mitochondrial functional activity, and stimulates autophagy. Consistently, the lack of glucose as well as its metabolically inert analogue 2-deoxy-D-glucose (2-DG), which inhibits hexokinase 2 (HK2), trigger autophagy through mTOR inhibition, and prevents IL-6-induced cell migration. Of clinical relevance, bioinformatic analysis of The Cancer Genome Atlas dataset revealed that ovarian cancer patients bearing mutated TP53 with low expression of glycolytic markers and IL-6 receptor, together with markers of active autophagy, display a longer overall survival and are more responsive to platinum therapy. Taken together, our findings demonstrate that RV can counteract IL-6-promoted ovarian cancer progression by rescuing glycolysis-mediated inhibition of autophagy and support the view that targeting Warburg metabolism can be an effective strategy to limit the risk for cancer metastasis.

Ovarian Cancer Cell-Conditioning Medium Induces Cancer-Associated Fibroblast Phenoconversion through Glucose-Dependent Inhibition of Autophagy

One aspect of ovarian tumorigenesis which is still poorly understood is the tumor–stroma interaction, which plays a major role in chemoresistance and tumor progression. Cancer-associated fibroblasts (CAFs), the most abundant stromal cell type in the tumor microenvironment, influence tumor growth, metabolism, metastasis, and response to therapy, making them attractive targets for anti-cancer treatment. Unraveling the mechanisms involved in CAFs activation and maintenance is therefore crucial for the improvement of therapy efficacy. Here, we report that CAFs phenoconversion relies on the glucose-dependent inhibition of autophagy. We show that ovarian cancer cell-conditioning medium induces a metabolic reprogramming towards the CAF-phenotype that requires the autophagy-dependent glycolytic shift. In fact, 2-deoxy-D-glucose (2DG) strongly hampers such phenoconversion and, most importantly, induces the phenoreversion of CAFs into quiescent fibroblasts. Moreover, pharmacological inhibition (by proline) or autophagy gene knockdown (by siBECN1 or siATG7) promotes, while autophagy induction (by either 2DG or rapamycin) counteracts, the metabolic rewiring induced by the ovarian cancer cell secretome. Notably, the nutraceutical resveratrol (RV), known to inhibit glucose metabolism and to induce autophagy, promotes the phenoreversion of CAFs into normal fibroblasts even in the presence of ovarian cancer cell-conditioning medium. Overall, our data support the view of testing autophagy inducers for targeting the tumor-promoting stroma as an adjuvant strategy to improve therapy success rates, especially for tumors with a highly desmoplastic stroma, like ovarian cancer.

21Works
2Papers
6Collaborators
Ovarian NeoplasmsCell Line, TumorLeukemia, Myeloid, AcutePrognosisBiomarkers, TumorCancer-Associated FibroblastsTumor Microenvironment

Positions

2023–

Post Doctoral Researcher

Università degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Scienze della Salute · Scienze della salute

Education

2022

Dottorato di Ricerca in Scienze e Biotecnologie Mediche

Università degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Scienze della Salute · Scienze della Salute

2019

Laurea Magistrale in Biologia

Università degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Scienze e Innovazione Tecnologica · Scienze e Innovazione Tecnologica

2017

Laurea Triennale in Scienze Biologiche

Università degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Scienze e Innovazione Tecnologica · Scienze e Innovazione Tecnologica